Hisilicon: Huapufen Injection Approved for Expanded Use in Children

Huawei announced that its subsidiary, Shenyang Huawei Pharmaceutical Co., Ltd., recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The application for propofol injection meets the relevant requirements for drug registration and has been approved for use in the induction and maintenance of general anesthesia in children/adolescents, with revised safety information in the instructions.